Not provided
Not provided
Not provided
Not provided
Not provided
The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
| Roche Farma, S.A | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and therefore treatment discontinuation probabilities in these patients. We propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.
The combination of bosutinib and atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and consequently treatment discontinuation probabilities in these patients. We would like to propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bosutinib-Atezolizumab Combination | Experimental | Drugs to be administered: Bosutinib 400 milligram (mg)/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bosutinib 400 MG Monotherapy | Drug | One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Safety Profile of Bosutinib 400 mg Daily in Combination With Atezolizumab in Participants With Chronic Myeloid Leukemia as First Line Treatments | All Adverse Events, despite their severity or causal relationship with the study medication, will be reported, graded according CTCAE v5.0 and analyzed. | through study completion, up to 7 months |
| Measure | Description | Time Frame |
|---|---|---|
| To Evaluate the Molecular Response (MR) Rates | Ratio of patients that reach a Molecular response | 7 months |
| Percentage of Participants Alive | Percentage of patients that remain alive at different time-points over the total number or patients |
Not provided
Inclusion Criteria:
Male or female patient ≥ 18 years of age.
Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study.
Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Newly Patient with Philadelphia chromosome positive chronic phase CML and BCR-ABL1 transcript detected at diagnosis.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
Adequate hepatic, renal and pancreatic function defined as:
Women of childbearing potential must have a negative pregnancy test documented prior enrollment. Women of childbearing potential and men must be using an adequate method of contraception.
Exclusion Criteria:
Pregnant or lactating women,
Participation in another clinical trial with any investigational drug within 30 days prior to study enrollment,
Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea,
Period of time since CML diagnosis longer than 6 months,
Hypersensitivity to the active substances or to any of the excipients of the bosutinib and/or atezolizumab formulations,
Major surgery or radiotherapy within 14 days of enrollment,
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease,
Concomitant use of or need for medications known to prolong the QTc interval,
Concomitant use with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin), moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem), or strong CYP3A inducers (rifampin, carbamazepine, phenytoin),
History of clinically significant or uncontrolled cardiac disease, including:
Grade III or IV fluid retention,
Uncontrolled hypomagnesemia or uncorrected symptomatic hypokalemia, due to potential effects on the QTc interval,
Uncontrolled or symptomatic hypercalcemia,
Recent or ongoing clinically significant gastrointestinal (GI) disorder e.g. Crohn's Disease, Ulcerative Colitis or prior total or partial gastrectomy,
Autoimmune or infectious active disease that require treatment,
CML patient not in chronic phase at diagnosis,
Patients with known atypical transcript. An atypical transcript is defined by the presence of any transcript in the absence of the major transcripts b3a2 (e14a2) and b2a2 (e13a2) or p210 protein,
Patients with known resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V). It is not necessary to perform mutation tests on the patient to be included in the study if they were not previously performed,
Individuals with an active malignancy,
Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive) and/or hepatitis C.
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.
Patients with severe renal impairment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Valentin Garcia, Dr. | Hospital Ramon y Cajal | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Ramón y Cajal | Madrid | 28034 | Spain | |||
| Hospital Universitario La Paz |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Bosutinib-Atezolizumab Combination | Drugs to be administered: Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year Bosutinib 400 MG Monotherapy: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 5, 2021 | Nov 17, 2022 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection | Drug | 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles |
|
|
| 7 months |
| Number of Confirmed MR4 and MR4.5 | Total number of patients that reach Molecular response 4 (MR4) and Molecular Response 4.5 (MR4.5) | 7 months |
| The Rate of Confirmed MR4 and MR4.5 | Ratio of patients that reach MR4 and MR4.5 | 7 months |
| Number of Complete Cytogenetic Responses (CCyR) | Number of patients that reach a Complete Cytogenetic Responses (CCyR) | 7 months |
| The Rate of Complete Cytogenetic Response (CCyR) | Ratio of patients that reach a Complete Cytogenetic Responses (CCyR) | 7 months |
| Days to Response (CCyR, MMR, MR4, MR4.5) | Number of days lasted since the beginning of the treatment upt to reach molecular response. | 7 months |
| The Median Time to Response (CCyR, MMR, MR4, MR4.5) | Average elapsed time measured for all included patients since the beginning of the treatment up until reach measurable cytogenetic or molecular response | 7 months |
| Probability of Response (CCyR, MMR, MR4, MR4.5) | The overall estimated probability of reaching complete cytogenetic response or molecular response MMR, MR4 or MR4.5 | 7 months |
| Number of Overall Surviving Patients | Number of the overall surviving patients | 7 months |
| Number of Progression-free Survival Patients | The following events are considered disease progression:
| 7 months |
| Number of Failure-free Survival Patients | Number of the failure-free survival patients | 7 months |
| Number of Event-free Survival Patients | Number of the event-free survival patients | 7 months |
| Phenotypical Assays of Cell Characterization | Phenotypical assays of the cell characterization | 7 months |
| Phenotypical Assays of Differentiation, Maturation and Proliferation NK Cells Markers | Phenotypical assays of the differentiation, maturation and proliferation NK cells markers | 7 months |
| Phenotypical Assays of CD4+ T Cells Activation Markers | Phenotypical assays of the CD4+ T cells activation markers | 7 months |
| Phenotypical Assays of Predictive Markers of CML Relapse | Phenotypical markers assessment for relapse included
| 7 months |
| Madrid |
| 28046 |
| Spain |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Bosutinib-Atezolizumab Combination | Drugs to be administered: Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year Bosutinib 400 MG Monotherapy: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Geometric Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| BCR-ABL | The study's main variable is BCR-ABL ratio. The measurement of BCR-ABL1 mRNA levels were done by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in peripheral blood. The results are reported as the ratio (percentage) of BCR-ABL protein (Mutated to normal ABL protein, expressed as % in the international scale [IS]) a scale developed for standardized reporting of BCR-ABL1 RNA levels. BCR-ABL1 IS = BCR-ABL1 transcript number/ABL1 transcript number × 100% × conversion coefficient (calculated for each case according to laboratory procedures and the specific calibration curve) | Mean | Standard Deviation | IS (%) |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Safety Profile of Bosutinib 400 mg Daily in Combination With Atezolizumab in Participants With Chronic Myeloid Leukemia as First Line Treatments | All Adverse Events, despite their severity or causal relationship with the study medication, will be reported, graded according CTCAE v5.0 and analyzed. | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol for safety reasons were reached. Therefore no sufficient data were obtained to conduct an efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. | Posted | Number | Total No Adverse events recorded | through study completion, up to 7 months |
|
|
| ||||||||||||||||||||||||||
| Secondary | To Evaluate the Molecular Response (MR) Rates | Ratio of patients that reach a Molecular response | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Alive | Percentage of patients that remain alive at different time-points over the total number or patients | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Confirmed MR4 and MR4.5 | Total number of patients that reach Molecular response 4 (MR4) and Molecular Response 4.5 (MR4.5) | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | The Rate of Confirmed MR4 and MR4.5 | Ratio of patients that reach MR4 and MR4.5 | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Complete Cytogenetic Responses (CCyR) | Number of patients that reach a Complete Cytogenetic Responses (CCyR) | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | The Rate of Complete Cytogenetic Response (CCyR) | Ratio of patients that reach a Complete Cytogenetic Responses (CCyR) | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Days to Response (CCyR, MMR, MR4, MR4.5) | Number of days lasted since the beginning of the treatment upt to reach molecular response. | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | The Median Time to Response (CCyR, MMR, MR4, MR4.5) | Average elapsed time measured for all included patients since the beginning of the treatment up until reach measurable cytogenetic or molecular response | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
| ||||||||||||||||||||||||||||||
| Secondary | Probability of Response (CCyR, MMR, MR4, MR4.5) | The overall estimated probability of reaching complete cytogenetic response or molecular response MMR, MR4 or MR4.5 | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Overall Surviving Patients | Number of the overall surviving patients | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Progression-free Survival Patients | The following events are considered disease progression:
| The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Failure-free Survival Patients | Number of the failure-free survival patients | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Event-free Survival Patients | Number of the event-free survival patients | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Phenotypical Assays of Cell Characterization | Phenotypical assays of the cell characterization | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Phenotypical Assays of Differentiation, Maturation and Proliferation NK Cells Markers | Phenotypical assays of the differentiation, maturation and proliferation NK cells markers | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Phenotypical Assays of CD4+ T Cells Activation Markers | Phenotypical assays of the CD4+ T cells activation markers | The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Phenotypical Assays of Predictive Markers of CML Relapse | Phenotypical markers assessment for relapse included
| The study had to be prematurely terminated due to drug toxicity; the stopping rules detailed in the protocol were reached. Therefore no sufficient data were obtained to conduct the planned efficacy analysis. No study subjects could be analysed for any of the efficacy outcomes. Study has to be prematurely terminated and the analysis could not be done due to lack of data (n=0 Participants). | Posted | 7 months |
|
Study Period: start (first patient enrolled) 24/02/2021 and premature end (Last patient last visit) 24/09/2021. Therefore, 7 months was the duration of this study and in this period of time when adverse event data were collected.
During the study all patients reported, at least 1 AE, and at least 1 AE considered possibly, probably or definitely related to the study medication. The system most frequently affected by AE, according to SOC MedDRA organization, was, Gastrointestinal Disorders, but the most severe AEs (grade 3 and above) were those affecting the liver function. All the possibly related events were previously described as adverse reactions in the product's data sheets (Bosulif SmPC and Tencentriq SmPC).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bosutinib-Atezolizumab Combination | Drugs to be administered: Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year Bosutinib 400 MG Monotherapy: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles | 0 | 9 | 4 | 9 | 9 | 9 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hepatotoxicity | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
| |
| Cholestasis | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
| |
| Transaminases Elevation | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
| |
| Abdominal discomfort | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
| |
| Abdominal pain | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
| |
| Abdominal pain upper | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
| |
| Blood bilirubin increased | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA | Non-systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA | Non-systematic Assessment |
| |
| Lipase increased | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA | Non-systematic Assessment |
| |
| Alanine aminotransferase increased | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
| |
| Aspartate aminotransferase increased | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Valentín García | ZERO LMC | 91 336 86 86 | jvalentingg@gmail.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 6, 2021 | Nov 17, 2022 | SAP_001.pdf |
| ID | Term |
|---|---|
| D015466 | Leukemia, Myeloid, Chronic-Phase |
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009196 | Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C471992 | bosutinib |
| C000594389 | atezolizumab |
| D007267 | Injections |
| ID | Term |
|---|---|
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Participants |
|
| Participants |
|
| Participants |
|
|
| Participants |
|
| Participants |
|
| Participants |
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
| Participants |
|
|
| Participants |
|
|
|
| Participants |
|
| Counts |
|---|
| Participants |
|
| Participants |
|
|